Seattle Genetics (SGEN) Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026


Go back to Seattle Genetics (SGEN) Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

November 12, 2019 5:15 PM UTC

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has submitted an arbitration demand to the American Arbitration Association to resolve its dispute with Daiichi Sankyo Co. Ltd. regarding the ownership of certain technology used by Daiichi Sankyo in its metastatic breast cancer drug candidate (DS-8201, [Fam-] trastuzumab deruxtecan), among... More